Homocysteine and cardiovascular disease: Cause or effect?

American Journal of Clinical Nutrition

Volumn 72, Issue 2, 2000, Pages 315-323

  Brattstrom, L ^a   Wilcken, D E L ^a  

^a KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Folic acid; Homocysteine; Methylenetetrahydrofolate reductase; Oxidative stress; Renal function; Thromboembolism

Indexed keywords

FOLIC ACID ANTAGONIST; HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; HUMAN; KIDNEY FUNCTION; REVIEW;

EID: 0033853452     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/72.2.315     Document Type: Review

References (139)

1. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995
2. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
3. Inborn errors of folate metabolism
4. Homocystinuria presenting with sagittal sinus thrombosis in infancy
5. Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings
6. Homocystinuria presenting as sagittal sinus thrombosis
7. De subitaneis mortibus, IV
8. Pathological findings in homocystinuria
9. Cerebral thrombosis in a patient with homocystinuria
10. Homocystinuria
11. Homocystinuria
12. Homocystinuria. A recently discovered cause of mental defect and cerebrovascular thrombosis
13. Homocystinuria
14. Homocystinuria. I. A clinical and pathological study of nine subjects in six families
15. Homocystinuria
16. Homocystinuria and atherosclerosis
17. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
18. Homocysteine
19. The natural history of vascular disease in homocystinuria and the effects of treatment
20. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control
21. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: Effect of CBS genotype on biochemical and clinical phenotype and on response to treatment
22. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
23. Homocysteine and cardiovascular disease
24. Homocysteinemia due to folate deficiency
25. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry
26. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency
27. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis
28. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
29. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
30. Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading
31. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease
32. Hyperhomocysteinemia: An independent risk factor for vascular disease
33. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease
34. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria
35. Vitamins as homocysteine-lowering agents
36. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations
37. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease
38. Serum folate and risk of fatal coronary heart disease
39. Serum folate and chronic disease risk: Findings from a cohort of United States adults
40. Serum folate and risk for ischemic stroke
41. Serum folate and risk for coronary heart disease: Results from a cohort of US adults
42. The association of vitamin B 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: The Bronx Aging Study
43. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: Results among U.S. men
44. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease
45. Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease
46. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians
47. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene
48. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
49. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12, and folate
50. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment
51. Hyperhomocyst(e)inaemia: An independent risk factor for intermittent claudication
52. Hyperhomocysteinaemia in stroke: Prevalence, cause, and relationships to type of stroke and stroke risk factors
53. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50 - Effect of smoking and extent of disease
54. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folate
55. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease
56. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
57. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis
58. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: Results from the third National Health and Nutrition Examination Survey, 1988-1994
59. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
60. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study
61. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects
62. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction
63. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
64. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
65. Vitamins B6, B12, and folate: Association with plasma total homocysteine and risk of coronary atherosclerosis
66. Vitamin intake: A possible determinant of plasma homocyst(e)ine among middle-aged adults
67. Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease?
68. Homocysteine and risk of cardiovascular disease among post-menopausal women
69. Plasma homocysteine and cardiovascular disease
70. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction
71. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease
72. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke
73. Methylenetetrahydrofolate reductase polymorphism (C-677T) and coronary artery disease
74. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study
75. Methylenetetrahydrofolate reductase gene polymorphism: Relation to blood pressure and cerebrovascular disease
76. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese
77. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate
78. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease
79. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: A case-control study
80. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke
81. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM
82. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area
83. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults
84. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis
85. Methylene tetrahydrofolate reductase C677T genotype and stroke
86. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project
87. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
88. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
89. Hyperhomocysteinemia in premature arterial disease: Examination of cystathionine beta-synthase alleles at the molecular level
90. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases
91. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study
92. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration
93. High homocysteine levels are independently related to isolated systolic hypertension in older adults
94. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients
95. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease
96. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study
97. A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study
98. Blood pressure and end-stage renal disease in men
99. The kidney as part of the cardiovascular system
100. Relationship between hypertension and renal function and its therapeutic implications in the elderly
101. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years
102. Relationship between vascular disease and age-associated changes in the human kidney
103. Homocysteine and cysteine: Determinants of plasma levels in middle-aged and elderly subjects
104. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus
105. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine
106. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C
107. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
108. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure
109. Net uptake of plasma homocysteine by the rat kidney in vivo
110. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine
111. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria
112. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis
113. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease
114. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects
115. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
116. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease
117. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis
118. The C677T MTHFR variant and the risk of venous thrombosis
119. Effect of the MTHFRC677T variant on risk of venous thromboembolism: Interaction with factor V Leiden and prothrombin (F2G20210A) mutations
120. Search for genetic factors favoring thrombosis in Turkish population
121. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes
122. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty
123. No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene
124. The mutation Ala677 Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
125. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease
126. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506)
127. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism
128. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects
129. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation
130. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents
131. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
132. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
133. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy
134. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation
135. Future for folates in cardiovascular disease
136. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
137. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease
138. Vitamins and homocysteine in cardiovascular disease and aging